A supplement combining cartilage hydrolysate and rosehip peel extract did no better than a placebo on the measure its own trial set as the main test, according to results published in Frontiers in Sports and Active Living on 23 October 2026. The randomised, double-blind study ran at a single centre in Dijon, France, between November 2024 and May 2025, and analysed 138 physically active adults aged 30 to 65 who reported knee discomfort during activity but had no diagnosed osteoarthritis. Pain after a standardised single-leg step-down test fell by 2.2 points in the supplement group and 2.4 points in the placebo group over eight weeks, a difference of -0.2 points with a 95% confidence interval of -1.1 to 0.7. The authors wrote that the supplement "did not demonstrate superiority over placebo for the primary endpoint". The study was funded by Symrise, which sells the ingredient, and four of its eight authors are Symrise employees with, in their own words, a commercial interest in the supplement studied.
What the secondary findings showed
The paper also reports secondary and exploratory results, and treats them cautiously. Among the 21% of participants who were postmenopausal women, step-down pain fell 3.4 points against 1.2 on placebo, a gap the paper records at p = 0.0712, above the conventional significance threshold. Across the whole cohort, pain during exertion was lower in the supplement arm at p = 0.0255. The authors acknowledge that pain fell much more than expected in both supplemented arms, which they attribute to a strong placebo effect, that most of the remaining effects were trends rather than significant results, and that the subgroup analysis ran multiple tests, which inflated the risk of a false positive. They call for larger studies before the postmenopausal finding is relied on. The trial was submitted to ClinicalTrials.gov as NCT06714851 on 22 November 2024, three days before it started, and the record was posted on 4 December 2024.
What this means for your supplement routine
The headline finding and the subgroup findings point in different directions, and coverage tends to lead on the subgroup. The trade write-up that carried this paper on 28 October was headlined “Cartilage and Rosehip Supplement Fails Primary Test but Hints at Benefit for Older Women”. The paper itself reports the primary endpoint first and says plainly that it was not met. The authors’ own note about a strong placebo effect applies to any short trial of a product taken for everyday aches, not only to this one. Nothing here tells you anything about a specific product on a shelf. It does suggest an order for reading the next trial that gets reported, which is to find the primary endpoint before the subgroup. Perqen shows the member price alongside the standard price on product pages and product cards across its full product catalogue.
How Perqen members save
Membership costs £4.99 a month or £29.99 a year and unlocks member pricing across the catalogue, while non-members buy at standard prices. The arithmetic on whether that pays for itself on a normal monthly order is set out on the membership pricing page.
This article reports published news and research and is for information only. Food supplements are not a substitute for a varied diet or medical care, and no product mentioned is intended to diagnose, treat, cure or prevent any disease. Speak to your GP or pharmacist before changing what you take, especially if you are pregnant, breastfeeding, or taking prescribed medicines.
Sources
- Supplementation with cartilage hydrolysate and rosehip peel extract in physically active adults: main outcomes and exploratory findings of a randomized, placebo-controlled study on knee discomfort (Frontiers in Sports and Active Living, 23 October 2026)
- Chondractiv Move on Activity-related Joint Discomfort (MOVIPLUS) trial registration, NCT06714851 - ClinicalTrials.gov
- Cartilage and Rosehip Supplement Fails Primary Test but Hints at Benefit for Older Women - Bioengineer.org